The morning news update with AstraZeneca, Hansteen Holdings and Chaarat Gold

FTSE 100

London Stock Exchange (LSE) – announces good year-on-year increases in activity across all main businesses for the 11 months to November.

AstraZeneca (AZN) – the European Commission has granted Marketing Authorisation for Lynparza™ (olaparib) capsules (400mg twice daily) as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy.

FTSE 250

Galliford Try (GFRD) – has been successfully appointed to the MoD’s Next Generation Estates Contract (NGEC) Framework for Capital Works Projects in Scotland. The four year framework is worth up to £250 million for projects with individual values of up to £12 million, and is extendable for a further three years. 

Hansteen Holdings (HSTN) – has completed the sale of eleven UK assets from the Ashtenne Industrial Fund , in which it has a 36.7% interest, for a combined price of £43.9 million, in three separate transactions. 

Riverstone Energy (RSE) –  announces an incremental commitment and investment in Castex Energy of approximately $150 million, comprised of approximately $100 million from Riverstone Global Energy and Power Fund V and approximately $50 million from Riverstone Energy Limited.

Small caps

SnackTime (SNAK) – EBITDA down by 21% to £0.4 million in the six months to September.

Chaarat Gold (CGH) – raises $5 million at a price of 15p per share, will enable the company to carry out the work needed to satisfy all the Kyrgyz regulatory requirements to secure construction permits for the Chaarat Project.

Brady (BRY) – two new customers have selected Brady solutions to support their business operations across the metals and energy space.

Real Good Food (RGD) – posts an EBITDA loss of £2.98 million for the six months to September.